In recent years, the global biopharmaceutical industry is developing rapidly. With a statistical analysis of the patents, this paper analyzes the current situation and the trend of the biopharma development, the focuses and the hotspots of the technological development, to provide a reference for the industrial decision-making and policy-making. The analysis shows that the global biopharma development is quite mature, and the development of anti-cancer drugs is still a hot spot in recent years. The United States is the innovation representative and the patent applications in China increase in recent years, though the quality remains to be improved. Companies are still the main force in the drug research and development, and the scientific research institutions are constantly providing new impetus to the biopharma industry. The CRISPR-Cas system, the PD-1/PD-L1 immunotherapy and the CAR T -cell therapy are leading technologies in this field.

Based on the double layer embeddedness theory and the knowledge spillovers theory, the E-TOMSDECT analysis model is proposed in this paper. With this model, the risks of China's open source software ecosystem are analyzed systematically. Based on a generalization analysis of international experiences of building open source software ecosystem, some recommendations are proposed. It is shown that our problems include the lack of the key core technology and the ecosystem operation pattern, insufficiencyt motivation, security risks and weak leadership in the international open source software ecosystem, the coordination of the software and the hardware, the inadequate software value evaluation system, the lack of professional talents for ecosystem operation, and underutilization of international experiencere. The urgent tasks in China include building a three-in-one leading core on emerging fields, strengthening the coordination of the software and the hardware, building the security risk assessment and emergency response mechanism, and strengthening the talent training.

The disruptive technology is an important force to achieve the breakthrough development of national scientific and technological innovation capabilities. Countries such as the United States and Japan have already planned for the development of the disruptive technology, and China is still in the initial exploration stage. By reviewing the experience of the disruptive technology financing in the major western developed countries, combined with the actual state of China's science and technology management, this paper finds that the bureaucracy in the scientific and technological plan management system, the traditional evaluation criteria and methods, and the attitude of "seeking quick success and instant benefits" of scientific research project management hinder the development of the disruptive technology in China. Based on the above review, this paper puts forward some suggestions, including the establishment of the special funded offices, the innovative science and technology project formation mechanisms and the funding methods, and the improvement of scientific and technological project management mechanisms, for science and technology managers at all levels.

The Belt and Road Initiative (BRI) projects are currently concentrated in the fields of infrastructure, agrochemicals, investment and development, and recreation and sports. This paper systematically analyzes the risks of geopolitics, legal system, customs and religious beliefs of countries along the BRI regions in macro and meso levels, as well as the risks of China's investment and financing systems, standards and rules docking, and international investment experience. On this basis, combined with Hong Kong's unique advantages, it is proposed that Hong Kong can play the roles of a financing center, an international arbitration platform, a consulting service platform, an international exchange platform, and a rule docking platform in the risk management of the BRI projects.